Universidad Peruana Cayetano Heredia

Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices

Mostrar el registro sencillo del ítem

dc.contributor.author Roque Perez, Katia Mercedes
dc.contributor.author Ruiz, Rossana
dc.contributor.author Más López, Luis Alberto
dc.contributor.author Pozza, Daniel Humberto
dc.contributor.author Vancini, Marina
dc.contributor.author Silva Júnior, José Antônio
dc.contributor.author de Mello, Ramon Andrade
dc.date.accessioned 2023-10-12T15:30:09Z
dc.date.available 2023-10-12T15:30:09Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/14299
dc.description.abstract The introduction of immunotherapy has brought about a paradigm shift in the management of advanced non-small cell lung cancer (NSCLC). It has not only significantly improved the prognosis of patients but has also become a cornerstone of treatment, particularly in those without oncogenic driver mutations. Immune checkpoint inhibitors (ICIs) play a crucial role in the treatment of lung cancer and can be classified into two main groups: Anti-cytotoxic T lymphocyte antigen-4 (Anti-CTLA-4) and anti-T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti-PD-L1). Certainly, the landscape of approved first line immunotherapeutic approaches has expanded to encompass monotherapy, immunotherapy-exclusive protocols, and combinations with chemotherapy. The complexity of decision-making in this realm arises due to the absence of direct prospective comparisons. However, a thorough analysis of the long-term efficacy and safety data derived from pivotal clinical trials can offer valuable insights into optimizing treatment for different patient subsets. Moreover, ongoing research is investigating emerging biomarkers and innovative therapeutic strategies that could potentially refine the current treatment approach even further. In this comprehensive review, our aim is to highlight the latest advances in immunotherapy for advanced NSCLC, including the mechanisms of action, efficacy, safety profiles, and clinical significance of ICI. en_US
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartofseries Cancers
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Immune checkpoint inhibitors en_US
dc.subject ICIs en_US
dc.subject Non-small cell lung cancer en_US
dc.subject NSCLC en_US
dc.subject PD-1 en_US
dc.subject PD-L1 en_US
dc.subject CTLA-4 en_US
dc.subject Oncogenic driver mutation en_US
dc.subject Treatment sequencing en_US
dc.subject Tumour biomarkers en_US
dc.subject Personalized medicine en_US
dc.subject.mesh Inhibidores de Puntos de Control Inmunológico
dc.subject.mesh Carcinoma de Pulmón de Células no Pequeñas
dc.subject.mesh Dolor en Cáncer
dc.subject.mesh Neoplasia Residual
dc.subject.mesh Medicina de Precisión
dc.title Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.3390/cancers15184547
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.21
dc.relation.issn 2072-6694


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas